Physician profile
Peter W Trottier
NPI 1235112947
$8,176.61
in general payments reported to CMS, 2019-2025
47 companies · $1,210 in 2025
The $1,210 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,822 · 2020: $1,121 · 2021: $1,014 · 2022: $562 · 2023: $974 · 2024: $1,473 · 2025: $1,210.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,658.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,657.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,200.75 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $822.54 | 2019-2025 | Evenity, Prolia, Repatha |
| Abbvie INC. | $722.66 | 2019-2025 | Vraylar, Ubrelvy, Synthroid |
| Pfizer INC. | $628.02 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $625.54 | 2019-2024 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $372.12 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Sanofi-Aventis U.S. LLC | $344.66 | 2019-2025 | |
| Lilly USA, LLC | $281.44 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $258.79 | 2019-2022 | |
| Astellas Pharma US INC | $249.36 | 2019-2025 | Veozah |
| Exact Sciences Corporation | $228.31 | 2023-2025 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $224.10 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $218.36 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $167.48 | 2019-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $145.45 | 2019-2025 | Jardiance |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $134.59 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $117.46 | 2023-2025 | Gemtesa |
| Janssen Pharmaceuticals, INC | $116.12 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $114.47 | 2022-2024 | Gvoke Hypopen |
| Dexcom, INC. | $107.40 | 2022-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $101.23 | 2019-2025 | Freestyle Libre 3 |
| Inspire Medical Systems, INC. | $100.70 | 2024 | Inspire |
| Allergan, INC. | $92.31 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $88.99 | 2019-2023 | Belsomra, Steglatro |
| Esperion Therapeutics, INC. | $73.36 | 2020-2025 | Nexletol |
| Shield Therapeutics INC | $60.66 | 2022-2024 | Accrufer |
| Eisai INC. | $55.55 | 2020-2021 | |
| Ironwood Pharmaceuticals, INC | $44.19 | 2019-2020 | |
| Gilead Sciences, INC. | $43.19 | 2020-2025 | |
| Pulmonx Corporation | $40.98 | 2024-2025 | Zephyr Endobronchial Valve, Chartis Catheter, Zephyr Delivery Catheter |
| Kowa Pharmaceuticals America, INC. | $37.80 | 2020-2021 | |
| Phathom Pharmaceuticals, INC. | $33.74 | 2024-2025 | Voquezna |
| Teva Pharmaceuticals USA, INC. | $33.62 | 2019 | |
| Corium, LLC | $33.55 | 2023 | Adlarity |
| Biohaven Pharmaceuticals, INC. | $30.24 | 2021 | |
| Dynavax Technologies Corporation | $26.51 | 2025 | Heplisav-B |
| Abiomed | $26.49 | 2025 | |
| Aytu Biopharma, INC. | $22.83 | 2020 | |
| Calliditas Therapeutics US INC. | $22.11 | 2025 | Tarpeyo |
| Sunovion Pharmaceuticals INC. | $20.77 | 2021 | |
| Hikma Pharmaceuticals USA | $20.20 | 2019 | |
| Sanofi Pasteur INC. | $16.31 | 2020 | |
| Becton, Dickinson and Company | $15.74 | 2022 | |
| Amneal Pharmaceuticals LLC | $15.57 | 2019 | |
| Antares Pharma, INC. | $15.36 | 2023 | Nocdurna, Xyosted, Tlando |
| Radius Health, INC. | $12.78 | 2020 | |
| Shire North American Group INC | $12.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Trottier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.